Darifenacin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Darifenacin.svg | |
| Darifenacin
| |
| Systematic (IUPAC) name | |
| 2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl] pyrrolidin-3-yl] -2,2-diphenyl-acetamide | |
| Identifiers | |
| CAS number | |
| ATC code | G04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C28H30N2O2 |
| Mol. mass | 426.55 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 15 to 19% (dose-dependent) |
| Protein binding | 98% |
| Metabolism | Hepatic (CYP2D6- and CYP3A4-mediated) |
| Half life | 13 to 19 hours |
| Excretion | Renal (60%) and biliary (40%) |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Darifenacin | |
|
Articles | |
|---|---|
|
Most recent articles on Darifenacin Most cited articles on Darifenacin | |
|
Media | |
|
Powerpoint slides on Darifenacin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Darifenacin at Clinical Trials.gov Clinical Trials on Darifenacin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Darifenacin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Darifenacin Discussion groups on Darifenacin Patient Handouts on Darifenacin Directions to Hospitals Treating Darifenacin Risk calculators and risk factors for Darifenacin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Darifenacin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.
Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.
It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.(1)
Administration
Darifenacin is administered as a once-daily extended-release oral tablet.
References
(1) SPC for emselex-revised on 29/11/06 (available at www.medicines.org.uk)
de:Darifenacin
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

